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Abstract
Interferon alpha (IFNa) therapy, despite good efficacy in curing HCV infection, leads to major side effects, in particular
inducement of a strong peripheral T-cell lymphocytopenia. We here analyze the early consequences of IFNa therapy on
both thymic function and peripheral T-cell homeostasis in patients in the acute or chronic phase of HCV-infection as well as
in HIV/HCV co-infected patients. The evolution of T-cell subsets and T-cell homeostasis were estimated by flow cytometry
while thymic function was measured through quantification of T-cell receptor excision circles (TREC) and estimation of
intrathymic precursor T-cell proliferation during the first four months following the initiation of IFNa therapy. Beginning
with the first month of therapy, a profound lymphocytopenia was observed for all T-cell subsets, including naı ¨ve T-cells and
recent thymic emigrants (RTE), associated with inhibition of intrathymic precursor T-cell proliferation. Interleukin (IL)-7
plasma concentration rapidly dropped while lymphocytopenia progressed. This was neither a consequence of higher
consumption of the cytokine nor due to its neutralization by soluble CD127. Decrease in IL-7 plasma concentration under
IFNa therapy correlated with the decline in HCV viral load, thymic activity and RTE concentration in blood. These data
demonstrate that IFNa-based therapy rapidly impacts on thymopoiesis and, consequently, perturbs T-cell homeostasis.
Such a side effect might be detrimental for the continuation of IFNa therapy and may lead to an increased level of infectious
risk, in particular in HIV/HCV co-infected patients. Altogether, this study suggests the therapeutic potential of IL-7 in the
maintenance of peripheral T-cell homeostasis in IFNa-treated patients.
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Introduction
The hepatitis C virus (HCV) causes persistent infection in
approximately two thirds of cases leading to chronic liver disease,
liver failure, and, eventually, hepatocellular carcinoma in a
substantial proportion of infected individuals. The most common
therapy for chronic hepatitis C consists of pegylated interferon-a
(IFNa) and ribavirin administration which results in viral
clearance in 43–46% (genotype 1) to 80%, (genotype 3) of treated
patients [1]. Interferon will continue to be a major component of
new direct acting antivirals for treatment of HCV [2].
IFNa is produced in large amounts during the acute phase of
many viral infections [3,4,5,6]. Direct activation of interferon-
stimulated genes enhances naı ¨ve T-cell survival through increased
Bcl-2 and reduced Bax activation [7] and contributes to clonal
expansion of antigen-specific T-cells [8]. Recent data suggest that
early therapeutic intervention with pegylated IFNa rescues
polyfunctional memory T-cells expressing high levels of the IL-7
receptor alpha chain (CD127) and Bcl-2, allowing a higher rate of
sustained viral response [9]. However, despite good efficacy,
IFNa-based therapies lead to sustained anemia, thrombocytope-
nia, neutropenia and lymphocytopenia [10,11,12,13,14]. More-
over, pegylated IFNa therapy enhances the risk of infection in
older HCV-infected patients and HIV-infected individuals,
independently from neutropenia [15,16,17].
The mechanisms of action of IFNa include inhibition of
different hematopoietic growth factors [18,19], possibly affecting
lymphoid differentiation at an early stage [20], and modifications
in cell homing [12,21,22]. The mechanisms involved in IFNa
therapy-associated leukocyte depletion remain poorly understood.
Others and we have documented a strong reduction in the
ability of HIV-infected patients to sustain thymic production as a
direct consequence of a drop in intrathymic precursor T-cell
proliferation [23,24,25]. Similar thymic impact was also seen
during early SIV-infection in the rhesus macaque model [26]. The
capacity of the thymus to produce recent thymic emigrants (RTEs)
is, in large part, dependent on thymocyte proliferation [27].
Indeed, extensive thymocyte proliferation occurs between T-cell
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The extent of this proliferation directly correlates with thymic
export [28]. The extent of cell proliferation in the thymus can be
measured in patients through estimating, in peripheral blood cells,
the ratio (sj/bTREC ratio) between the frequency of signal joint
T-cell receptor excision circles (sjTREC), produced during the
excision of the TCRd locus prior to TCRa chain rearrangement,
and that of DbJbTREC T-cell receptor excision circles (TRECs)
produced during TCRBD to TCRBJ rearrangement [29]. These
by-products of TCR rearrangement processes are generated by
the circularization of the chromosomal DNA excised during TCR
rearrangements respectively occurring at the DN3 (DbJbTREC)
and DP (sjTREC) stages of differentiation. Due to the fact that
TRECs do not replicate during mitosis, increased proliferation
between DN3 and DP leads to the reduction of DbJbTREC
frequency in RTEs as compared to sjTREC frequency and
consequently to an increase of the sj/bTREC ratio [23]. The
correlation between initial plasma IFNa levels and the speed of
thymic dysfunction observed during HIV primary infection
suggested that IFNa, produced as part of the innate immune
response to infection, participates in the impairment of thymopoi-
esis. However, no direct evidence of the relationship between
IFNa production and thymic dysfunction was provided by these
studies. In contrast, Arizcorreta and colleagues showed that IFNa
and ribavirin therapy induces a substantial reduction of circulating
sjTRECs, in HIV/HCV co-infected patients, accompanied by
sustained naı ¨ve CD4
+ T-cell defect, suggesting thymic dysfunction
[10]. Similarly, in the SIV-infected rhesus macaque model, we
showed that IFNa therapy induced a strong decrease of circulating
RTE numbers as defined either by sjTREC frequency and
numbers or by CD31
hi expression on naı ¨ve T-cells [30].
Interestingly, in these animals, recombinant interleukin (IL)-7
therapy more than abrogated the deleterious effects of IFNa
therapy [30].
IL-7 is a key cytokine implicated at various levels of thymocytes
differentiation. It allows cell survival during the rearrangement
processes, and is implicated in the extensive thymocyte prolifer-
ation, in particular in intermediate single positive (ISP) and early
DP cells [31,32,33,34]. This proliferation participates in the
development of naı ¨ve T-cell diversity [35]. While up regulated by
IFNa [36,37], the cyclin-dependent kinase inhibitor P27/Kip1 is
negatively regulated by IL-7 [38], allowing ISP and early DP
thymocytes to proliferate. Moreover, IFNa also inhibit IL-7
dependent proliferation through down modulation of the common
c chain, that participates, together with CD127 to the IL-7
receptor [39]. We here investigated the early impact of IFNa
therapy on thymic function and naı ¨ve T-cell homeostasis in both
HCV-infected and HIV/HCV co-infected patients who started
IFNa therapy.
Results
IFNa treatment alters circulating naı ¨ve T-cell subsets
We first evaluated the evolution of naı ¨ve T-cell subsets in three
groups of HCV infected individuals: 1) Acute HCV infection
(n=8), defined as ,6 months post estimated date of infection; 2)
chronic HCV infection (n=8), defined as .6 months post
estimated date of infection; and 3) HIV/HCV co-infected
individuals (n=10). In all groups, patients were enrolled at the
beginning of IFNa therapy and were followed for a total of
4 months. While, for any group of patient’s, naı ¨ve CD4+ and
CD8+ T-cell counts were not significantly different from healthy
individuals (figure 1A), as early as one month following treatment
initiation, naı ¨ve CD4+ T-cell counts were significantly reduced in
chronically HCV-infected patients (39%, 58%, 46% and 35%
decrease at M1, M2, M3 and M4 respectively; p#0.025;
Figure 1B, top central panel). A similar trend was also observed
in the CD8 compartment (40%, 39%, 33% and 33% decrease;
Figure 1B, bottom central panel). A comparable effect was also
observed in most co-infected patients (mean cell count declines
were 19%, 32%, 52% and 43% at M1, M2, M3 and M4 in the
CD4+ T-cell compartment and 9%, 21%, 41% and 42% in CD8+
T-cell subset; p#0.05 by M2–M3; Figure 1B, right panels). In
contrast, naı ¨ve T-cell counts were only barely affected in acutely-
HCV infected patients under IFNa therapy (Figure 1B, left
panels). Similarly, central memory CD4+ T-cells (CD45 RA-
CCR7+; TCM) demonstrated 38% and 28% decrease in HCV
and HIV/HCV patients respectively (59% and 60% in CD8+
TCM) while effector memory (CD45RA2 CCR7–; TEM) CD4+
T-cell counts declined by 45% and 10% in the same groups (61%
and 65% in CD8+ TEM) (Figure S1).
Within CD4+ naı ¨ve T-cells, RTEs can be identified by their
higher expression of the platelet endothelial cell adhesion
molecule-1 (PCAM-1 or CD31) [40]. While the number of RTEs
was similar in HCV-infected patients at study entry and healthy
individuals (Figure 2A, top panel), the proportion of CD31hi cells
in naı ¨ve CD4+ (CD45RA+ CCR7+) T-cells was significantly
reduced by M1 in acutely HCV-infected patients (p,0.05 at all
time points). Together with the decline in naı ¨ve T-cell counts, this
translated into reduced numbers of circulating RTE (p#0.05 by
M2; Figure 2B, top left panel). Similarly, chronically HCV-
infected patients demonstrated lower absolute numbers of CD31hi
naı ¨ve T-cells by M1 (p#0.012; Figure 2B, central panel). In the
co-infected patients group, despite more limited variations in the
percentage of RTEs in naı ¨ve T-cells (p#0.05 at M1 and M4), the
absolute RTE counts also declined with time under therapy
(p#0.05 at M2, M3 and M4; Figure 2B, right panel).
RTE concentration in blood can also be estimated through
quantification of the sjTREC content (sjTREC/mL, Figure 2,
bottom panels). sjTREC content was in the range of age matched
healthy individuals at baseline (figure 2A) but declined significantly
in both subgroups of HCV-infected patients by one month
following initiation of IFNa therapy (median=5034, 4104, 2980,
2805 and 3076 sjTREC/mL at M0, M1, M2, M3 and M4
respectively in acutely HCV-infected patients; p,0.05 and
median=3879, 1895, 2018, 1511 and 1040 sjTREC/mL at M0,
M1, M2, M3 and M4 respectively in chronically HCV-infected
patients; p,0.05; Figure 2B, left and central bottom panels). In
contrast, HIV/HCV infected patients demonstrated more stable
sjTREC/mL values that eventually declined at M4 (median
=4192, 5215, 4420, 3871 and 1597 sjTREC/mL at M0, M1, M2,
M3 and M4 respectively (p=0.046 at M4); Figure 2B, right
bottom panel).
These data demonstrate that, as early as one month following
treatment initiation, IFNa induces stronger alterations of naı ¨ve T-
cell subsets, and more specifically in the RTE compartment than
in any other T-cell subset, suggesting a specific effect on
thymopoiesis. We thus analyzed the evolution of intrathymic
precursor T-cell proliferation, peripheral T-cell cycling, IL-7
plasma concentration and IL-7 receptor alpha chain (CD127)
expression, different factors affecting naive T-cell homeostasis.
IFNa therapy affects thymic function
Despite differences between the 3 groups at study entry, RTE
cycling rate, as estimated through measurement of Ki-67
expression, did not change significantly during the follow-up
period (Figure 3A). These data demonstrate that the observed
changes in sjTREC frequencies were not a consequence of
IFNa-Therapy Alters Thymopoiesis
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probably due to reduced thymic production.
We thus estimated thymic output through quantification of the
sj/bTREC ratio in all groups of patients (Figure 3B). The sj/
bTREC ratio estimates the extent of thymocyte proliferation
between TCRB rearrangement and the excision of the T-cell
receptor delta (TCRD) locus [23]. This parameter directly reflects
the extent of thymic production and, contrarily to sjTREC values,
is independent from peripheral RTE proliferation or survival
capacity [28]. The sj/bTREC ratio was already low in HIV-
infected patients (p,0.005 as compared to healthy control donors;
Figure 3B bottom left panel) and did not evolve further under
IFNa therapy in co-infected patients (Figure 3B, bottom right
panel). In contrast, acutely HCV-infected patients demonstrated
higher than normal sj/bTREC ratio at baseline (p,0.05 as
compared to aged matched healthy controls), showed a significant
reduction in sj/bTREC ratio at M1 (p=0.014) and M2
(p=0.001; Figure 3B, top panel). Finally, a similar decline in the
sj/bTREC ratio was observed during IFNa therapy in chronically
HCV-infected patients (p,0.02 at M1, M2 and M3; Figure 3B,
central panel).
Reduction of IL-7 plasma levels under IFNa treatment
Precursor T-cell proliferation in the thymus is, at least in part,
dependent upon IL-7. We thus quantified plasma IL-7 concen-
tration in all groups of patients. At study entry, HCV- and HIV/
HCV-infected patients presented with elevated plasma IL-7
(median=10.3 pg/mL, range (6.7–12.9) in acutely HCV-infected
patients; 8.3 pg/mL (6.3–10.5) in chronic HCV-infected patients
and 7.15 pg/mL (4.3–13.5) in co-infected subjects), as compared
to that observed in healthy control individuals (p,0.001 for any
patients’ group; Figure 4A). Surprisingly, while lymphocytopenia
established, IL-7 plasma concentrations significantly decreased in
both groups of HCV-infected patients (30, 54, 18 and 29%
decrease at M1 to M4 in acute infection, p,0.05; 25, 46, 26 and
16% decrease at M1 to M4 in chronic infection, p,0.05; Figure 4B
left and central panels). In contrast, IL-7 plasma levels did not
significantly evolve in co-infected individuals during the first
month of IFNa therapy (Figure 4B right panel). Only patients with
the highest IL-7 plasma levels showed a reduction in the
concentration of this cytokine.
Decreased plasma IL-7 concentrations could be a consequence
of reduced IL-7 production, increased consumption by T-cells or
sequestration by soluble IL-7 receptor (sCD127). In both HCV-
infected and HIV/HCV co-infected patients, neither sCD127
Figure 1. IFNa therapy leads to naı ¨ve T-cell lymphocytopenia. (A) CD4
+ (top panel) and CD8
+ (bottom panel) naı ¨ve T-cell counts were
quantified in peripheral blood cells from acutely HCV-infected (light grey symbols), chronically HCV-infected (black symbols) and HIV/HCV co-infected
(white symbols) patients at study entry, as compared to healthy donors (HCV-, dark grey symbols). (B) Evolution of CD4
+ (top panels) and CD8
+
(bottom panels) naı ¨ve T-cell counts during the first 4 months of IFNa therapy in acutely HCV-infected (left panels), chronically HCV-infected (central
panels) and HIV/HCV co-infected (right panels) patients. Each line represents data from an individual patient. Statistical significances of the
differences to baseline values (time 0), calculated on the absolute naı ¨ve T-cell counts in each individual sample, (Wilcoxon matched-pairs signed-ranks
test) are shown on top. The horizontal bars represent median values.
doi:10.1371/journal.pone.0034326.g001
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or CD8+ T-cells (Figure 4D) significantly changed during IFNa
therapy.
Evolution of Thymic function parallels IL-7 plasma levels
Considering the variations in all the parameters we used to
evaluate thymic function, we then sought to evaluate the impact of
changes in IL-7 plasma levels on de novo production from the
thymus and on the number of both sjTREC and circulating CD4+
RTEs.
In a majority of patients, IL-7 plasma level, sj/bTREC ratio,
sjTREC/ml and blood RTE concentration fluctuated in parallel
(Figure S2). Variation of IL-7 plasma concentration (DIL-7)
during the first month of therapy correlated with variations in
naı ¨ve T-cell counts (CD4++CD8+; DNaı ¨ve T-cell counts) and
RTE CD4+ T-cell counts (DRTE T-cell counts) in both HCV
(r=0.521, p=0.039 and r=0.595, p=0.025; Figure 5A and 5B,
left panels) and, to a lesser extent, HIV/HCV co-infected patients
(r=0.636, p=0.048 and r=0.539, p=0.108; Figure 5A and 5B,
right panels). Moreover, in HCV-infected patients, DIL-7 also
correlated with variations in intrathymic precursor T-cell
proliferation (Dsj/bTREC ratio; r=0.601, p=0.020; Figure 5C).
Variations in plasma IL-7 levels also correlated with changes in
the proportions (D%Ki-67+ in CD4+RTEs; r=0.806, p=0.0002;
Figure 5D, left panel) and numbers (DKi-67+RTEs; r=0.706,
p=0.002; Figure 5E, left panel) of cycling RTEs in acute and
chronic HCV infected patients and with D%Ki-67+RTE counts in
co-infected patients (r=0.709, p=0.022; Figure 5E, right panel).
Overall, IL-7 concentration was associated with reduced thymo-
poiesis and RTE proliferation, lower consequently leading to
limited circulating RTE and naı ¨ve T-cell counts. These data
strongly suggest that changes in IL-7 plasma levels during IFNa
therapy directly impact the homeostasis of RTEs.
Discussion
We herein demonstrated that IFNa-based therapy leads to
major lymphocytopenia in naı ¨ve T-cell compartments, in
particular in the RTE subset. Several mechanisms could be
implicated in the establishment of such a lymphocytopenia [41].
Among these, enhanced apoptosis [42,43], cell sequestration in
lymphoid or non-lymphoid organs [12,21,22] and regulation of
peripheral T-cell homeostasis [20]. In our study, no major change
in cell survival (Bcl-2 expression) or T-cell activation (CD25 and
CD69 expression) was observed during the follow-up period (data
not shown). Moreover, we did not observe any significant
modification in Ki-67 expression in any T-cell subset during the
first month of therapy (data not shown and Figure 3). Finally,
Figure 2. IFNa therapy reduces recent thymic emigrant blood counts. (A) Recent thymic emigrant counts (RTE/ml, top panel) and sjTREC
concentration (TRECs/ml, bottom panel) were quantified in peripheral blood cells from acutely HCV-infected (light grey symbols), chronically HCV-
infected (black symbols) and HIV/HCV co-infected (white symbols) patients at study entry, as compared to healthy donors (HCV
2, dark grey symbols).
(B) Evolution of (RTE/ml, top panels) and sjTREC concentration (TRECs/ml, bottom panels) during the first 4 months of IFNa therapy in acutely HCV-
infected (left panels), chronically HCV-infected (central panels) and HIV/HCV co-infected (right panels) patients. Each line represents data froma n
individual patient. Statistical significances of the differences to baseline values (time 0), calculated on the absolute RTE CD4
+ T-cell counts and sjTREC
levels in each individual sample (Wilcoxon matched-pairs signed-ranks test) are shown on top. The horizontal bars represent median values.
doi:10.1371/journal.pone.0034326.g002
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a transient process [22] suggesting that this mechanism marginally
contributes to the observed long lasting lymphocytopenia.
Interestingly, both sjTREC quantification (sjTREC/mL) and
intrathymic precursor T-cell proliferation (sj/bTREC ratio) were
affected very early on after initiation of therapy (Figures 2B and
3B). While sjTREC frequency and concentration in peripheral
blood can be affected by modifications of parameters that impact
on peripheral T-cell homeostasis (cycling, survival/apoptosis,
homing), the sj/bTREC ratio is a marker of the intrathymic
proliferation history of RTEs. Indeed, this parameter is generated
by cell proliferation that occurs between TCRb chain rearrange-
ment and the excision of TCRd locus. Further cell cycling after
TCRa chain rearrangement does not modify the sj/bTREC ratio
as both type of TRECs are similarly diluted upon cell
proliferation. Accordingly, while exported to the periphery, the
sj/bTREC ratio of mature T-cells cannot be modified. Therefore,
while the observed decrease in sjTREC concentration (figure 2)
can be a consequence of modifications of circulating T-cell
homeostasis, the decline of the sj/bTREC ratio observed during
the first months of IFNa therapy (figure 3) defines changes in
thymocyte proliferation, thus in thymic output [28]. Acutely
infected patients demonstrated a higher sj/bTREC ratio at
baseline than patients in the chronic phase. However, this group
was younger (Median=31.5 (26–47)) versus Median=53.5 (37–
61)) than the chronic group (p,0.01; data not shown) and
demonstrated normal sj/bTREC ratio for their age. Similar
evolution of thymic function and circulating T-cell subsets were
observed in both groups of HCV-infected patients, irrespective of
the development stage of HCV pathology. The lack of effect of
IFNa therapy in HIV/HCV co-infected patients might be due to
the fact that, as expected for chronically HIV-infected individuals,
these patients already had a low thymic function at study entry.
The impairment of thymopoiesis in HCV-infected patients under
IFNa therapy is reminiscent of that observed during the acute
phase of HIV-1 infection [23] which suggested that long term
production of IFNa, as part of the anti-HIV innate immune
response, may play a role in the observed thymic defect. The
Figure 3. IFNa therapy leads to major impairment of thymic function. (A) The frequency of Ki-67 expressing cells in the CD4
+ RTE subset
(CD31
hi naı ¨ve T-cells) was measured in acutely HCV-infected (grey symbols, top panel), chronically HCV-infected (white symbols, top panel) and HIV/
HCV co-infected (bottom panel) patients (central panels) and HIV/HCV co-infected (right panels) patients. Each line represents data from an individual
patient. Statistical significances of the differences to baseline values (time 0), calculated on the absolute sj/bTREC ratio in each individual sample
(Wilcoxon matched-pairs signed-ranks test) are shown on top. The horizontal bars represent median values.
doi:10.1371/journal.pone.0034326.g003
IFNa-Therapy Alters Thymopoiesis
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34326correlation between decline in IL-7 plasma levels under IFNa
therapy and both thymic dysfunction and reduced T-cell counts,
in particular in the naı ¨ve and RTE compartments (Figures 5A and
5B), confirms this hypothesis. Finally, in a recent study, we showed
that IFNa treatment leads to decreased sjTREC frequency as well
as reduced naı ¨ve T-cell and RTE counts in SIV-infected rhesus
macaques [30]. Such an effect was accompanied by a 30–40%
decrease in IL-7 plasma levels in these animals and could be
counteracted by injection of recombinant simian IL-7 [30]. One
could expect that such an effect of type I IFNs is not restricted to
HIV-infection as many viral infections induce IFNa responses and
cause transient lymphocytopenia in the infected hosts [3,4,5,6].
Moreover, the IFNa-induced reduction of thymic function and its
probable consequences on naı ¨ve T-cell diversity may contribute to
the higher infectious risk associated with IFNa therapy, in
particular observed in older patients [15,16,44]. There are
multiple sources for circulating IL-7 during viral infections
including lymphoid organs, epithelial cells and recently the liver
was identified as a major source of IL-7. Moreover, increased
plasma IL-7 levels can also be observed during viral infection in
non-lymphopenic individuals ([33] and unpublished data), sug-
gesting a role in the development of immune responses. Indeed,
this cytokine participates to T-cell homing in various lymphoid
and non-lymphoid tissues through stimulation of local chemokine
Figure 4. IFNa therapy leads to reduction in IL-7 plasma concentration. (A) IL-7 plasma levels were quantified in peripheral blood cells from
acutely HCV-infected (light grey symbols), chronically HCV-infected (black symbols) and HIV/HCV co-infected (white symbols) patients at study entry,
as compared to healthy donors (HCV-, dark grey symbols). **: p,0.001 for any HCV-infected patients group. (B) Evolution of plasma IL-7 levels over
the first 4 months of IFNa therapy in acutely HCV-infected (left panels), chronically HCV-infected (central panels) and HIV/HCV co-infected (right
panels) patients. Each line represents an individual patient. Statistical significances of the differences to baseline values (time 0), calculated on the
absolute IL-7 plasma levels in each individual sample (Wilcoxon matched-pairs signed-ranks test) are shown on top. (C) Soluble CD127 was quantified
in plasma from acutely HCV-infected (white symbols, top panel), chronically HCV-infected (black symbols, top panel) and HIV/HCV co-infected
(bottom panel) patients at baseline (0) and M2. (D) CD127 expression was measured on circulating CD4
+ (top panel) and CD8
+ (bottom panel) and
expressed as mean fluorescence intensity (left panels) and percentages of positive cells (right panels) over the 4 first months of IFNa therapy.
doi:10.1371/journal.pone.0034326.g004
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individuals is likely due to reduced consumption [46] yet
augmented production to counteract lymphopenia cannot be
excluded [33]. The recent identification of the liver as an IL-7
producing tissue upon TLR stimulation [47] makes it tempting to
speculate that HCV-infection can also, through TLR activation,
stimulate IL-7 production by the liver. Indeed, non-lymphopenic
HCV-infected patients demonstrate similar IL-7 plasma levels
than lymphopenic HIV-infected individuals [33,48] suggesting
that most of the IL-7 production in untreated HCV-infected
patients was not linked to circulating T-cell counts. The reduction
of IL-7 plasma levels while lymphocytopenia establishes under
IFNa therapy, the absence of a correlation between IL-7 plasma
levels and CD127 expression and the concomitance of decreases in
IL-7 plasma levels and HCV viral load under therapy suggest that
viremia might be driving IL-7 production before initiation of
therapy. Our data suggest that, before initiation of IFNa therapy,
actively replicating HCV leads to the overproduction of IL-7.
Subsequent reduction of IL-7 production upon initiation of
therapy probably reflects the elimination of IL-7 producing
HCV-infected hepatocytes. This sudden reduction of IL-7 plasma
levels may lead to diminished thymopoiesis. The fact that IL-7
plasma levels did not reach normal levels when HCV became
undetectable may suggest that, after the initial decline that follows
the drop in viremia, IL-7 plasma levels were regulated, as in HIV-
infected patients [33] and in IFNa-treated SIV-infected rhesus
macaques [30], as a consequence of lymphocytopenia through
either reduced consumption or increased production in lymphoid
organs [49]. Future studies with a longer follow-up period, in
particular after the end of IFNa therapy and recovery from
lymphocytopenia are required to further elucidate this point.
We herein demonstrated that a substantial reduction in thymic
export was observed in HCV-infected patients, during the first
months of IFNa therapy. This effect directly paralleled IFNa-
induced lymphocytopenia and decreased IL-7 plasma levels,
initially high in HCV-infected patients. These data suggest that
IL-7 production by the liver, a consequence of active HCV
replication, was reduced while patients controlled HCV viremia.
Restricted IL-7 plasma levels might, in association with the anti-
proliferative effect of IFNa, limit T-cell production in the thymus.
Our study highlights the therapeutic potential of IL-7 as a
complement to the standard IFNa based treatment to help HCV-
infected patients to sustain normal circulating T-cell counts, and
restore the diversity of the peripheral T-cell repertoire through its
central thymopoietic effect. Restoring the breadth and intensity of
T-cell control over the HCV virus might be immediately beneficial
for the HIV/HCV co-infected population and offer new
promising avenues for chronic HCV in the context of massive
drop of HCV viral load after short term treatment with new
antiviral compounds that will continue to be administered in
combination with IFNa [50].
Patients and Methods
Patients characteristics
Sixteen HCV-infected patients (C-1 to C-16) and ten HIV/
HCV co-infected patients (I-1 to I-10) naı ¨ve to IFNa therapy were
enrolled in this study. A summary of the virological and
immunological status of patients at baseline is shown in table 1.
All the HIV/HCV co-infected patients but one were under
HAART with undetectable viremia (,40 HIV copies/mL).
Chronically infected patients (C-9 to C-16 and I-1 to I-10)
initiated pegylated IFNa/ribavirin treatment (IFNa-2a: Pegasys,
180 mg weekly, Ribavirin: Copegus, 800 mg to 1000 mg daily) and
were followed over a 4 months period. Patients included in the
acute phase of HCV infection (C-1 to C-8) were treated with
pegylated IFNa (IFNa-2a: Pegasys, Roche, 180 mg weekly)
[51,52]. Blood samples were taken monthly on EDTA. Two
milliliters of total blood were 2-fold diluted in FCS/20%DMSO
frozen at 280uC and conserved in liquid nitrogen. These total
blood samples were subsequently used for flow cytometry analyses.
Plasma was separated from the remaining eight milliliters and
mononuclear cells were purified on Ficoll Hypaque (Eurobio,
Courtaboeuf, France) and frozen for further analyses. Patients
from the HCV mono-infection group were followed at the Centre
de Recherche du CHUM, Ho ˆpital Saint Luc, Montreal, QC,
Canada and its collaborators as previously described [9,53].
Patients from the HIV-HCV groups were followed at the Ho ˆpital
Henri Mondor, Creteil, France. Clinical protocols conformed to
Figure 5. Variations in IL-7 plasma levels correlate with
evolution of RTE production. Correlations. between variations in
IL-7 plasma levels (DIL-7) and either variations in (A) total (CD4
+ + CD8
+)
naı ¨ve T-cell counts (Dnaı ¨ve T-cell counts), (B) RTE defined as CD31
hi
naı ¨ve CD4
+ T-cells (DRTE CD4 counts), (C) the sj/bTREC ratio (Dsj/bTREC
ratio), (D) the frequency of Ki-67
+ cells in the RTE CD4
+ T-cell subset
(D%Ki-67
+ in CD4
+ RTEs) or (E) the number of circulating Ki-67
+CD4
+
RTEs (DKi-67
+ RTE counts) between study entry and month 1 of therapy
were calculated for acutely (black symbols) and chronically (white
symbols) HCV-infected patients (left panels) and HIV/HCV co-infected
patients (right panels). Correlation coefficients (Spearman’s r) and the
associated probabilities (p) are shown.
doi:10.1371/journal.pone.0034326.g005
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Department of Health and Human Services’ human experimen-
tation guidelines. This study was approved by both the Ethical
committee of Centre Hospitalier de l’Universite ´ de Montreal
(CHUM) and the ethical committee of Ho ˆpital Henri Mondor,
Cre ´teil, France. Samples were obtained with the written subjects’
informed consent.
Immunophenotyping and flow cytometry analysis
FACS analyses were performed on cryopreserved samples. After
thawing blood cells were incubated for 15 minutes at 4uC with
conjugated monoclonal antibodies (mAbs). For intracellular
labeling, cells were permeabilized with the Cytofix/Cytoperm
Kit (Becton Dickinson) before incubation with specific mAbs
according to the manufacturer’s instructions. Samples were then
washed, fixed in 2% paraformaldehyde phosphate-buffered saline
(PBS/PFA 2%) and acquired using a Cyan cytofluorometer (Dako)
and analyzed with FlowJo 8.7 software.
The monoclonal antibodies used in this study were: CD3-pacific
blue (PB) (clone UCHT-1; Dako, Trappes, France), CD4-peridin
chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5) (clone L200; BD,
Le-Pont-de-Claix, France), CD45RA-phycoerythrin (PE) (clone
HI100; BD), CCR7-allophycocyanin (APC) (clone 150503; R&D
Systems Europe, Lille, France); CD8-phycoerythrin-cyanine 7
(PE-Cy7) (RPA-T8; BD), CD31-biotin (clone WM59; AbDSer-
otec, Du ¨sseldorf, Germany); Ki-67-fluorescein isothiocyanate
(FITC) (clone MIB-1; Dako), Bcl-2-FITC (clone 124; Dako) and
strepatavidin-PE-Texas-RED (BD).
IL-7 plasma quantification
IL-7 was quantified in the plasma using the IL-7 Quantikine HS
kit according to the manufacturer’s instructions (R&D Systems
Europe). Plasma soluble-CD127 quantification Soluble plasma IL-
7 receptor (sCD127) quantification was performed as previously
described [54].
TREC quantifications
Parallel quantification of the sjTREC and the 13 DJbTRECs,
together with CD3c gene (used as a housekeeping gene) was
performed for each sample using LightCyclerTM technology
(Roche Diagnostics) with a technique adapted from [29].
Table 1. Patients’ characteristics.
Patient Code Gender Age at Tx start HCV genotype HCV stage Baseline Viral load
a,b 12 weeks Viral load
C-1 F 33 3a Acute 2.4E+4
b ,50
c
C-2 M--.F 30 1 Acute 2.8E+4
b ,50
c
C-3 M 39 2b Acute ,1000
b ,50
c
C-4 M 26 3a Acute 4.78E+6
b ,50
c
C-5 M 26 1a Acute ,600
a ,50
c
C-6 M 31 1b Acute ,600
a ,50
c
C-7 M 46 3a Acute 1.56E+4
b ,50
c
C-8 M 45 1a Acute 1,21E+06
b ,50
c
C-9 M 36 1b Chronic 8,50E+06
a ,50
c
C-10 M 39 1a Chronic 1,28E+07
a ,50
c
C11 F 46 1a Chronic 8,26E+06
a ,50
c
C-12 M 52 1b Chronic 2,70E+06
a ,50
c
C-13 M 55 1a Chronic 4,79E+06
a 4,69E+03
a
C-14 M 58 1a Chronic 1,73E+07
a ,50
c
C-15 M 61 1a Chronic 3,70E+05
a ,50
c
C-16 M 61 1b Chronic 3,00E+06
a 3,47E+04
a
I-1 M 42 3 Chronic NA ,12
d
I-2 M 48 3a Chronic 1.51E+6 ,12
d
I-3 M 39 3 Chronic 7.6E+5 ,12
d
I-4 M 48 3a Chronic 6.4E+4 ,12
d
I-6 F 53 2a/2c Chronic 3.0E+6 ,12
d
I-7 M 43 2a/2c Chronic 4.3E+6 ,12
d
I-8 M 41 1 Chronic 6.7E+5 2.4E+5
I-9 M 43 1 Chronic 1.8E+6 ,12
d
I-10 M 41 4 Chronic 6.6E+5 1.6E+5
I-11 M 39 1 Chronic 7.7E+5 1.6E+4
aCOBAS Amplicor HCV Monitor test, Version 2.0 (sensitivity 600 IU/ml).
bIn house real time quantitative PCR assay (sensitivity 1000 IU/ml).
cQualitative COBAS AmpliPrep/COBAS Amplicor HCV test, version 2.0 (sensitivity 50 IU/ml).
dAbbott RealTime HCV assay (sensitivity 12 IU/ml).
NA: Not available.
doi:10.1371/journal.pone.0034326.t001
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calculation of the sj/bTREC ratio as described [23].
HCV RNA quantification
HCV RNA quantification was performed using an in-house
quantitative real-time reverse transcription-PCR assay as previ-
ously described [9], COBAS Amplicor HCV Monitor test
TM,
Version 2.0 (sensitivity 600 IU/ml)), qualitative COBAS Ampli-
Prep/COBAS Amplicor HCV test
TM, version 2.0 (sensitivity
50 IU/ml) or Abbott RealTime HCV assay
TM (sensitivity 12 IU/
ml).
Statistical analysis
Statistical analyses (Spearmans rank correlations and Wilcoxon
matched -paired signed-rank tests) were performed using the
Stata/IC 10.0 (Stata corporation, College Station, Tx U.S.A.).
Due to the exploratory nature of the study there was no correction
for multiple comparisons, and calculated p values are reported
herein.
Supporting Information
Figure S1 IFNa therapy leads to T-cell lymphopenia in
memory compartments. Evolution of (A) CD4+ TCM (top
panels) and CD4+ TEM (bottom panels) T-cell numbers, as well as
(B) CD8+ TCM (top panels) and CD8+ TEM T-cell counts
(bottom panels), quantified in peripheral blood cells from acutely
and chronically HCV-infected (left panels white and grey symbols
respectively) and HIV-HCV co-infected (right panels) patients
under IFNa therapy. Horizontal bars represent median values.
Statistical significance (Wilcoxon matched-pairs signed-ranks test)
to baseline values (M0) are shown on top.
(TIF)
Figure S2 IL-7 plasma level parallels RTE concentra-
tion and thymic function. IL-7 plasma levels (grey squares),
RTE (CD31
Hi naı ¨ve CD4+ T-cell blood counts; open diamonds),
thymic function (sj/bTREC ratio; close diamonds) and sjTREC
concentrations (sjTREC/ml; grey diamonds) were longitudinally
quantified in IFNa-treated HCV and HIV-HCV infected patients
over a 4 month period. Representative examples of HCV-infected
(A) and HIV-HCV co-infected (B) patients are shown.
(TIF)
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